Amgen INC Form 4 insider transactions

Amgen's EVP of Global Commercial Operations, Murdo Gordon, disposed of 6,691 shares of common stock to cover tax obligations at a price of $366.21 per share.

Amgen's Chairman, CEO, and President, Robert A. Bradway, disposed of 21,294 shares of common stock at $366.21 per share to cover tax liabilities.

Amgen's VP of Finance and CAO, Matthew C. Busch, disposed of 327 common shares at $366.21 each to cover tax liabilities.

Amgen's Chairman, CEO, and President, Robert A. Bradway, exercised stock options and adjusted his direct common stock holdings.

Amgen's EVP of Operations, Esteban Santos, reported the acquisition of 11,259 shares of common stock, primarily through equity compensation, effective March 3, 2026.

Amgen's EVP & Chief Technology Officer, David M. Reese, acquired 12,063 shares of common stock on March 3, 2026, increasing his beneficial ownership to 47,650 shares.

Amgen's SVP of Human Resources, Derek Miller, reported the acquisition of 3,484 shares of common stock, increasing his beneficial ownership to 13,744 shares.

Rachna Khosla, Amgen's SVP of Business Development, acquired 1,876 shares of common stock, increasing her direct beneficial ownership to 8,972 shares.

Amgen's Senior Vice President and Chief Compliance Officer, Nancy A. Grygiel, reported the acquisition of 2,010 shares of common stock.

Amgen's Executive Vice President and Chief Financial Officer, Peter H. Griffith, reported the acquisition of 12,063 shares of common stock through an equity grant.

Amgen's Executive Vice President and General Counsel, Jonathan P. Graham, reported a planned acquisition of 10,723 shares of common stock scheduled for March 3, 2026.

Amgen Inc.'s EVP of Global Commercial Operations, Murdo Gordon, acquired 13,403 shares of common stock, increasing his direct beneficial ownership.

Amgen's Chairman, CEO, and President, Robert A. Bradway, acquired 42,657 shares of common stock, increasing his direct beneficial ownership.

Amgen's VP of Finance and Chief Accounting Officer, Matthew C. Busch, reported the acquisition of 938 shares of common stock.

Amgen's EVP of Operations, Esteban Santos, exercised stock options and subsequently sold a portion of the acquired common stock to cover costs and taxes.

Amgen's VP of Finance and Chief Accounting Officer, Matthew C. Busch, reported the sale of 1,000 shares of common stock.

Amgen's EVP of Research and Development, James E. Bradner, reported a future disposition of common stock for tax obligations on February 9, 2026.

Amgen's Senior Vice President and Chief Compliance Officer, Nancy A. Grygiel, exercised and immediately sold stock options totaling 3,139 shares on November 20, 2025.

Amgen's SVP of Business Development, Rachna Khosla, sold 890 shares of common stock for approximately $336.24 per share under a pre-arranged trading plan.

Amgen's Executive Vice President of Global Commercial Operations, Murdo Gordon, reported the sale of 6,879 shares of common stock as part of a pre-arranged 10b5-1 plan.

Amgen's EVP & Chief Technology Officer, David M. Reese, reported gifting a total of 6,799 shares of common stock to charitable organizations.

Amgen Director Omar Ishrak acquired 218.6134 shares of common stock at no cost, increasing his beneficial ownership.

Amgen Director Charles M. Holley reported the acquisition of 265.4591 shares of common stock through a dividend reinvestment plan.

Amgen Inc. Director Michael V. Drake reported the acquisition of 218.6134 shares of common stock at a price of $0, increasing his beneficial ownership.

Amgen's SVP of Business Development, Rachna Khosla, reported a disposition of 226 common shares for tax withholding purposes related to equity vesting.

Amgen's VP of Finance and CAO, Matthew C. Busch, reported a pre-scheduled disposition of 202 common shares for tax liabilities at $296.7 per share, effective November 5, 2025, under a Rule 10b5-1 plan.

Amgen's Senior Vice President and Chief Compliance Officer, Nancy A. Grygiel, reported a planned sale of 1,267 shares of common stock for approximately $296.985 per share under a Rule 10b5-1 plan.

Amgen Inc. Director S. Omar Ishrak is set to acquire 121.4308 shares of common stock on August 8, 2025, through a pre-planned Restricted Stock Unit grant.

Amgen Inc. Director Charles M. Holley reported the acquisition of 147.4517 shares of common stock through an equity incentive program.

Amgen Director Michael V. Drake reported the acquisition of 121.4308 shares of common stock through a restricted stock unit grant, increasing his direct beneficial ownership to 4,699.0291 shares.